about
Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney diseaseSodium-hydrogen exchange inhibition attenuates glycoside-induced hypertrophy in rat ventricular myocytesRisk of digoxin intoxication in heart failure patients exposed to digoxin-diuretic interactions: a population-based study.In vitro efficacies of clinically available drugs against growth and viability of an Acanthamoeba castellanii keratitis isolate belonging to the T4 genotypeFrom a pump to a pore: how palytoxin opens the gates.Anti-digoxin Fab variants generated by phage display.Ouabain attenuates cardiotoxicity induced by other cardiac steroids.ATPases as drug targets: learning from their structure.Use of antiarrhythmic drugs in elderly patientsManagement of chronic heart failure: an old disease with a new face.Cardiac Glycoside Constituents of Streblus asper with Potential Antineoplastic Activity.Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarctionThe safety of digoxin as a pharmacological treatment of atrial fibrillation.Clinical pharmacokinetics and pharmacodynamics of vildagliptin.Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties.Role of Digoxin in Atrial Fibrillation.Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.Chronic digitalis therapy in patients before heart transplantation is an independent risk factor for increased posttransplant mortality.Ouabain is a potent promoter of growth and activator of ERK1/2 in ouabain-resistant rat renal epithelial cells.Use of digoxin in the treatment of chronic heart failure.No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers.Digoxin-associated decrease in parathyroid hormone (PTH) concentrations in patients with atrial fibrillation.Laboratory testing of clinically approved drugs against Balamuthia mandrillaris.Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation.
P2860
Q27011660-472229C7-6E46-4C1F-853A-302614630FBBQ28568918-F5CD49F2-3889-4647-9175-B30D22DC4314Q34026276-B0AAF4DB-A61C-41E0-A6BF-F4AA5E842EB7Q34344456-AF8A5848-EA81-4129-A9FB-ED4EF9B46634Q34469407-1AEA14EB-12AB-47F9-9215-521F9400A099Q34566178-F4F9887F-5037-46E2-8AC1-128F0491CA2AQ34659971-01D3ED93-90C5-446E-A12B-953693B192B9Q34810356-AA5B05CD-827A-4DFF-BD08-411BFA44B833Q36077245-76E08C3D-6B65-4231-9ED4-16BD6F3E7671Q36083086-D03F637C-C9FF-4493-83FD-D73082722B4FQ36226639-4A47EA9B-3037-4C0A-8BFE-B82CC0696CC4Q36321059-DE239222-501D-48BE-88A5-53393AFED060Q36446911-99DA5D35-7313-487E-AE44-6294DD8B0351Q37984567-EDE59D34-4002-42AD-AF88-72AE1ABF4ABBQ38127568-B6653804-A536-4BC5-B4D8-E03B818889FBQ38805268-857C9624-F2A8-40AC-8441-028940A3900EQ39247505-11CFDB74-16D8-48C6-AF17-E11054BF4F9BQ42673198-04C86252-E5AE-410A-93DF-F3F2C975AD6CQ44433293-5F8E887C-7AD6-450C-933E-B70B2E2C3AC3Q44923123-7F86A7A1-7C6E-40BB-A8CE-FBE210419A1AQ45001580-89402E81-BA0A-45D7-A8A4-4069A51E6C6CQ46747336-24CB5780-376E-4EE3-BD5F-F87126913580Q48755593-5EA382FB-FEB5-4AAF-B270-C224DD669AD3Q50634411-299A771A-5906-4F9F-9CE3-DCF87225228AQ51732455-521EB483-0DAF-4255-B6F5-7774ECC4430C
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Digoxin.
@ast
Digoxin.
@en
Digoxin.
@nl
type
label
Digoxin.
@ast
Digoxin.
@en
Digoxin.
@nl
prefLabel
Digoxin.
@ast
Digoxin.
@en
Digoxin.
@nl
P356
P1476
Digoxin.
@en
P2093
Eric J Eichhorn
P304
P356
10.1053/PCAD.2002.31591
P577
2002-01-01T00:00:00Z